Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin
- 1 September 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 11 (9) , 865-869
- https://doi.org/10.1089/105072501316973127
Abstract
Radioiodine ablation (RA) of normal thyroid remnants after thyroidectomy for differentiated thyroid carcinoma improves the sensitivity of subsequent radioiodine scans and serum thyroglobulin measurements for detection of residual thyroid carcinoma. Local cancer recurrences are also lower after RA. One standard preparation for RA involves rendering the patient hypothyroid in order to stimulate endogenous thyrotropin (TSH) secretion and sodium iodide symporter (NIS) activity. An alternative approach is to prescribe thyroxine after thyroidectomy and to stimulate NIS with exogenous recombinant human thyrotropin (rhTSH). This latter approach was used in 10 patients at our medical center. Complete resolution of all visible 131I thyroid bed uptake was achieved in all when follow-up scans were performed 5 to 13 months later. This approach has the potential to successfully ablate thyroid remnants without the need to induce hypothyroidism.Keywords
This publication has 20 references indexed in Scilit:
- Preparation by Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal Are Comparable for the Detection of Residual Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2001
- Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996Cancer, 2000
- A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or CancerJournal of Clinical Endocrinology & Metabolism, 1999
- Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma—a critiqueInternational Journal of Radiation Oncology*Biology*Physics, 1999
- The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinomaCancer, 1998
- Thyroid Remnant 131I Ablation for Papillary and Follicular Thyroid CarcinomaThyroid®, 1997
- Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinomaCancer, 1996
- Radioiodine Therapy for Thyroid CancerEndocrinology and Metabolism Clinics of North America, 1995
- Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study)Journal of Clinical Endocrinology & Metabolism, 1994
- The Effect of131I Therapy on Survival of Patients with Metastatic Papillary or Follicular Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 1973